The novel agent asciminib out-performed bosutinib in a phase III trial of patients with heavily pretreated chronic phase chronic myeloid leukaemia (CML), according to results presented at the ASH 2020 meeting. Asciminib is a first-in-class STAMP inhibitor that specifically targets the ABL myristoyl pocket. This differs from all approved tyrosine kinase inhibitors, which bind to ...
Novel STAMP inhibitor potentially practice changing in CML
By Dave Levitan
10 Dec 2020